MedTrace Logo

LAIV (Flumist®) Administration in CF Patients

NCT01885169 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2014-09-16

No results posted yet for this study

Summary

Influenza (the "flu") is one of the most common respiratory viruses associated with respiratory deteriorations in children and adolescents with cystic fibrosis. These deteriorations usually mean antibiotics, hospitalizations, and worsening of pulmonary function tests. A new flu vaccine has been recently approved for use in Canada (Flumist®). What is particular about this flu vaccine is that it is a spray in the nose, which mimics how influenza usually infects us. This particular vaccine protects children and adolescents much better than the regular injectable flu shot.

This new vaccine has been given to \> 2,000 healthy children and to \>2,000 children with asthma and well tolerated. The investigators want to know if Flumist® is well tolerated in children with CF and does not cause worsening of respiratory symptoms. The investigators will conduct a study where all participants will receive Flumist® in the nose. This study is particularly important because its results will provide safety information on a vaccine that is more efficacious for a population who needs safe and easy to administer protection against the flu.

Conditions

Interventions

BIOLOGICAL

Flumist®

The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.

Sponsors & Collaborators

  • Ministere de la Sante et des Services Sociaux

    collaborator OTHER

  • Canadian Cystic Fibrosis Foundation

    collaborator OTHER

  • PHAC/CIHR Influenza Research Network

    collaborator OTHER_GOV

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Caroline Quach-Thanh, MD, MSc · McGill University Health Centre/Research Institute of the McGill University Health Centre

  • Caroline Quach-Thanh, MD, MSc · McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-04-30
Completion
2015-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01885169 on ClinicalTrials.gov